Search PubMedSearch

PubMed · 6889832

Urge incontinence.

Abstract

Patients suffering from urge incontinence can present with very strong desire to void even with small bladder volumes. The syndrome is subdivided into two categories: motor and sensory urge incontinence. In motor urge incontinence uninhibited detrusor contractions are found, and this condition is mostly associated with neurological disorders. In sensory urge incontinence no uninhibited detrusor contractions are present, and the condition may be secondary to pathological conditions in the urogenital tract. In some of the patients with primary sensory urge incontinence an unstable urethra may be found. The treatment of urge incontinence is mainly by medication, but bladder drill has also given good results.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Moen, R Stien. 1982. Urge incontinence.. https://pubmed.ncbi.nlm.nih.gov/6889832/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA.

Gadodiamide injection, a new nonionic, MRI contrast medium, was compared with the ionic agent gadolinium (Gd)-DTPA at 0.1 mmol/kg body weight in a double-blind, randomised trial in 60 patients, 30 receiving each substance, with known or suspected lesions of the central nervous system. The patients were closely questioned about adverse events. In the Gadodiamide injection group, four patients reported six adverse advents, three of which were judged to be related to the contrast medium. In the Gd-DTPA group, two patients each reported one adverse event, both of which had an uncertain relation to the contrast medium. All events were mild and no medical treatment was needed. No significant change in neurological findings, blood pressure, pulse rate or blood parameters were noted in any patient. Both contrast media were effective; no difference in overall efficacy or safety was observed.

Central Nervous System Diseases